Who owns Vertex Pharmaceuticals (VRTX)? Superinvestor holders

5 superinvestors of the 157 tracked here hold Vertex Pharmaceuticals (VRTX) in their latest 13F filing, with $846.3M between them. Tweedy, Browne team gives it the most weight: 1.11% of the reported portfolio. In their latest reported quarter, Jim Simons (1938–2024), Israel Englander and Ken Griffin added; Tweedy, Browne team and Baillie Gifford team reduced.

Hold it now
5
of 157 tracked
Combined value
$846.3M
Bought / sold
3 / 2
last quarter

Key facts

Superinvestors holding it
5 of 157
Biggest holder
Ken Griffin, $253.5M
Largest weight
Tweedy, Browne team, 1.11%of their portfolio
Combined value
$846.3M
Bought last quarter
3
Sold last quarter
2

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding VRTX, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Tweedy, Browne teamTweedy, Browne Company1.11%$13.6M26.01K▼ Reduced 35%−14.11KQ3 2026
2Jim Simons (1938–2024)Renaissance Technologies0.28%$207.4M396.77K▲ Added 24%+76.77KQ3 2026
3Israel EnglanderMillennium Management0.16%$232.7M468.41K▲ Added more than 10×+437.59KQ2 2026
4Ken GriffinCitadel Advisors0.15%$253.5M510.43K▲ Added 50%+171.14KQ2 2026
5Baillie Gifford teamBaillie Gifford & Co0.13%$139.1M266.06K▼ Reduced 2.4%−6.51KQ3 2026

Quarter by quarter

Superinvestor ownership of VRTX by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 2026923688.84K$360.1M12
Q2 202615751.61M$800.5M32
Q1 20261573661.5K$295.4M13
Q4 20251574771.38K$349.7M23
Q3 202515741.01M$394.6M22
Q2 202515741.28M$569.3M14
Q1 202515651.68M$814.8M14
Q4 202415641.61M$649.6M14

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of VRTX held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Jim Simons (1938–2024)396.77K320.01K421.69K505.05K735.89K1M1.17M1.4M
Baillie Gifford team266.06K272.56K199.42K201.09K207.06K212.48K134.47K149.84K
Tweedy, Browne team26.01K40.12K40.39K39.15K39.07K37.25K38.32K40.63K
Ken Griffin·510.43K——————
Israel Englander·468.41K————309.94K—
Cathie Wood———26.1K25.67K24.06K26.34K25.35K

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own VRTX?

In their latest 13F filings: Tweedy, Browne team (1.11% of the portfolio, $13.6M), Jim Simons (1938–2024) (0.28% of the portfolio, $207.4M), Israel Englander (0.16% of the portfolio, $232.7M), Ken Griffin (0.15% of the portfolio, $253.5M), Baillie Gifford team (0.13% of the portfolio, $139.1M).

Who bought VRTX last quarter?

Jim Simons (1938–2024) (added 24%), Israel Englander (added 1,420%), Ken Griffin (added 50%). “Last quarter” is each investor's latest reported quarter.

Who sold VRTX last quarter?

Reduced: Tweedy, Browne team (35% fewer shares), Baillie Gifford team (2.4% fewer shares).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns Vertex Pharmaceuticals (VRTX)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/VRTX/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to VRTX by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.